Market Overview

Gilead Sciences Outlook Brightens; Citi Upgrades

Gilead Sciences Outlook Brightens; Citi Upgrades
Related GILD
IMX Dips In October, But Investors Remain Bullish
Investor Movement Index October Summary
Gilead And GS-9674 In PSC And NASH: To Itch Or Not To Itch (Seeking Alpha)

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharma company focused on treatments for HIV/AIDS, liver disease, cancer, inflammatory and respiratory, and cardiovascular conditions.

The Analyst

Citigroup analyst Robyn Karnauskas upgraded shares of Gilead Sciences from Neutral to Buy, with a $103 price target.

The Thesis

Hepatitis C Virus stabilization by mid-2018 and tax reform has improved the outlook for Gilead Sciences, Karnauskas said in a note.

Given the management's statement at the JPMorgan Healthcare Conference that HCV is becoming more predictable, the analyst said post-earnings the HCV numbers could become more reasonable.

Citi expects pipeline catalysts, with JAK-1 and NASH, or non-alcoholic steatohepatitis, to start outweighing HCV declines. The firm also sees plenty of pipeline catalysts, including:

  • NASH phase 2 readouts at the European Association for the Study of the Liver;
  • Major Phase 3 readout for STELLER 4 early next year; and
  • First Phase 3 readout for JAK-1 program likely in the second-half of 2018.

"All eyes would also be on Juno Therapeutics safety data and differentiation vs. Kite Pharma CAR-T in mid-2018," Karnauskas said. Gilead purchased Kite Pharma last October.

Price Action

Gilead Sciences shares are up over 22 percent over the past year. At time of writing, shares were down 1.8 percent to $87.20.

Related Links:

Pete Najarian Sees Unusual Options Activity In Gilead And KKR & Co

Pharma M&A Picks Up Momentum

Latest Ratings for GILD

Oct 2018Raymond JamesMaintainsStrong BuyStrong Buy
Oct 2018Cantor FitzgeraldMaintainsOverweightOverweight
Oct 2018PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Citigroup Robyn KarnauskasAnalyst Color Upgrades Analyst Ratings Best of Benzinga


Related Articles (GILD + JUNO)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Another Blockchain ETF Arrives, This Time With A Focus On Artificial Intelligence

This Day In Market History: AOL-Time Warner Reports Record Losses